$1.61
0.62% day before yesterday
Nasdaq, Sep 06, 10:00 pm CET
ISIN
US5288723027
Symbol
LXRX
Sector
Industry

Lexicon Pharmaceuticals, Inc. Target price 2024 - Analyst rating & recommendation

Lexicon Pharmaceuticals, Inc. Classifications & Recommendation:

Buy
67%
Hold
33%

Lexicon Pharmaceuticals, Inc. Price Target

Target Price $6.20
Price $1.61
Potential
Number of Estimates 5
5 Analysts have issued a price target Lexicon Pharmaceuticals, Inc. 2025 . The average Lexicon Pharmaceuticals, Inc. target price is $6.20. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 6 analysts: 4 Analysts recommend Lexicon Pharmaceuticals, Inc. to buy, 2 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Lexicon Pharmaceuticals, Inc. stock has an average upside potential 2025 of . Most analysts recommend the Lexicon Pharmaceuticals, Inc. stock at Purchase.

Sales and Margin forecast 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Revenue Million $ 1.20 16.40
757.14% 1,266.29%
EBITDA Margin -14,266.67% -1,304.00%
80.09% 90.86%
Net Margin -24,099.33% -1,489.77%
84.95% 93.82%

6 Analysts have issued a sales forecast Lexicon Pharmaceuticals, Inc. 2024 . The average Lexicon Pharmaceuticals, Inc. sales estimate is

$16.4m
Unlock
. This is
350.43% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$40.2m 1,004.45%
Unlock
, the lowest is
$10.1m 177.47%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2023 $1.2m 757.14%
2024
$16.4m 1,266.29%
Unlock
2025
$61.7m 276.55%
Unlock
2026
$152m 146.32%
Unlock
2027
$334m 119.90%
Unlock
2028
$570m 70.51%
Unlock

2 Analysts have issued an Lexicon Pharmaceuticals, Inc. EBITDA forecast 2024. The average Lexicon Pharmaceuticals, Inc. EBITDA estimate is

$-214m
Unlock
. This is
8.82% lower
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-213m 8.26%
Unlock
, the lowest is
$-215m 9.38%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2023 $-171m 70.64%
2024
$-214m 24.88%
Unlock
2025
$-163m 23.99%
Unlock
2026
$-61.4m 62.24%
Unlock

EBITDA Margin

2023 -14,266.67% 80.09%
2024
-1,304.00% 90.86%
Unlock
2025
-263.24% 79.81%
Unlock
2026
-40.36% 84.67%
Unlock

6 Lexicon Pharmaceuticals, Inc. Analysts have issued a net profit forecast 2024. The average Lexicon Pharmaceuticals, Inc. net profit estimate is

$-244m
Unlock
. This is
12.25% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-231m 16.88%
Unlock
, the lowest is
$-264m 5.19%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2023 $-289m 29.03%
2024
$-244m 15.54%
Unlock
2025
$-203m 16.92%
Unlock
2026
$-121m 40.33%
Unlock
2027
$78.3m 164.68%
Unlock
2028
$318m 306.17%
Unlock

Net Margin

2023 -24,099.33% 84.95%
2024
-1,489.77% 93.82%
Unlock
2025
-328.70% 77.94%
Unlock
2026
-79.62% 75.78%
Unlock
2027
23.42% 129.41%
Unlock
2028
55.79% 138.22%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Earnings Per Share $ -0.80 -0.68
29.03% 15.00%
P/E negative
EV/Sales 23.04

6 Analysts have issued a Lexicon Pharmaceuticals, Inc. forecast for earnings per share. The average Lexicon Pharmaceuticals, Inc. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

$-0.68
Unlock
. This is
11.69% higher
Unlock
than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is
$-0.64 16.88%
Unlock
, the lowest is
$-0.73 5.19%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2023 $-0.80 29.03%
2024
$-0.68 15.00%
Unlock
2025
$-0.56 17.65%
Unlock
2026
$-0.33 41.07%
Unlock
2027
$0.22 166.67%
Unlock
2028
$0.88 300.00%
Unlock

P/E ratio

Current -2.08 4.15%
2024
-2.38 14.42%
Unlock
2025
-2.87 20.59%
Unlock
2026
-4.81 67.60%
Unlock
2027
7.43 254.47%
Unlock
2028
1.83 75.37%
Unlock

Based on analysts' sales estimates for 2024, the Lexicon Pharmaceuticals, Inc. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

23.04
Unlock
and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of
35.50
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 103.77 83.81%
2024
23.04 77.80%
Unlock
2025
6.12 73.44%
Unlock
2026
2.48 59.40%
Unlock
2027
1.13 54.53%
Unlock
2028
0.66 41.35%
Unlock

P/S ratio

Current 159.89 84.16%
2024
35.50 77.80%
Unlock
2025
9.43 73.44%
Unlock
2026
3.83 59.40%
Unlock
2027
1.74 54.52%
Unlock
2028
1.02 41.35%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today